UY30042A1 - NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME. - Google Patents

NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.

Info

Publication number
UY30042A1
UY30042A1 UY30042A UY30042A UY30042A1 UY 30042 A1 UY30042 A1 UY 30042A1 UY 30042 A UY30042 A UY 30042A UY 30042 A UY30042 A UY 30042A UY 30042 A1 UY30042 A1 UY 30042A1
Authority
UY
Uruguay
Prior art keywords
new derivatives
alquilfosfolípidos
reduced cytotoxicity
same
treatment
Prior art date
Application number
UY30042A
Other languages
Spanish (es)
Inventor
Jurgen Engel
Mathias Pietras
Daniel Perrissoud
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05027823A external-priority patent/EP1800684A1/en
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of UY30042A1 publication Critical patent/UY30042A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nuevos derivadso de alquilfosfolepídos con citotoxicidad reducida que son de utilisdad para el tratamietno de diversas enfermedades y/o afecciones fisiopatológicas en mamíferos, preferentemente seres humanos, que son causadas por microorganismos, en particular bacterias, hongos, protozoos y/o virus. Dichos alquilfosfolípidos se pueden emplear como drogas individuales o en el transcurso de terapias combinadas y también se pueden usar para el tratamiento de tumores.New derivatives of alkyl phospholepids with reduced cytotoxicity that are useful for the treatment of various diseases and / or pathophysiological conditions in mammals, preferably humans, which are caused by microorganisms, in particular bacteria, fungi, protozoa and / or viruses. Such alkyl phospholipids can be used as individual drugs or in the course of combined therapies and can also be used for the treatment of tumors.

UY30042A 2005-12-19 2006-12-19 NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME. UY30042A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75143805P 2005-12-19 2005-12-19
EP05027823A EP1800684A1 (en) 2005-12-20 2005-12-20 Novel alkyl phospholipid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
UY30042A1 true UY30042A1 (en) 2007-07-31

Family

ID=37942171

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30042A UY30042A1 (en) 2005-12-19 2006-12-19 NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.

Country Status (13)

Country Link
EP (1) EP1962862B1 (en)
JP (1) JP5232009B2 (en)
KR (1) KR101378005B1 (en)
AR (1) AR058397A1 (en)
AU (1) AU2006328479B2 (en)
CA (1) CA2632449A1 (en)
HK (1) HK1124775A1 (en)
IL (1) IL191695A (en)
NO (1) NO20082862L (en)
PL (1) PL1962862T3 (en)
RU (1) RU2469727C2 (en)
UY (1) UY30042A1 (en)
WO (1) WO2007071658A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068037A1 (en) * 2006-12-08 2008-06-12 Jado Technologies Gmbh Cholesterylamines for the treatment and prevention of infectious diseases
DE102007014375A1 (en) 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. oleylphosphocholine
AT505515B1 (en) * 2007-08-02 2009-04-15 Orphanidis Pharma Res USE OF MILTEFOSINE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING CRYPTOSPORIDIOSIS IN HUMANS
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
ES2732941T3 (en) * 2011-03-04 2019-11-26 Oblita Therapeutics Bvba Oleylphosphocholine for the treatment of mycosis
CN102584926B (en) * 2012-01-12 2014-10-15 浙江大学 Method for preparing supermolecule hydrogel based on amphiphilic micromolecules (cholesterol and phosphorylcholine)
RU2487708C1 (en) * 2012-03-12 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) Method of treating parvoviral infection b19 in infants
CA3024129A1 (en) 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3076615A1 (en) 2017-09-21 2019-03-28 The Scripps Research Institute Novel therapies for treating and preventing chronic rhinosinusitis
ES2739773B2 (en) * 2018-08-02 2020-11-17 Univ Alicante ZWITTERIONIC COMPOUNDS OF 2-PHOSPHOCOLINE CARBOXYL ACIDS AND THEIR USE AS CYTOTOXIC AGENTS
CN115003309B (en) * 2019-12-02 2024-05-24 阿里量子解决方法公司 Crystal form of compound with structural formula I

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (en) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd Antitumor agent
CA1338627C (en) 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
EP0284395B1 (en) 1987-03-24 1993-06-23 Nippon Chemiphar Co., Ltd. Novel glycerol derivative and anti-hypertensive agent
DE3942933A1 (en) * 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh USE OF ALKYLPHOSPHOLIPIDES AS ANTIVIRAL MEDICINAL PRODUCTS AND NEW PHOSPHOLIPID DERIVATIVES
DE4111105A1 (en) * 1991-04-05 1992-10-08 Max Planck Gesellschaft NEW ERUCYL, BRASSIDYL AND NERVONYL DERIVATIVES
DE59205998D1 (en) * 1991-07-04 1996-05-23 Asta Medica Ag Medicament with antineoplastic activity containing octadecyl- [2- (N-methylpiperidino) ethyl] phosphate as active ingredient and process for its preparation
DE4132344A1 (en) 1991-09-27 1993-04-01 Max Planck Gesellschaft METHOD FOR PRODUCING A MEDAL FOR ORAL OR TOPICAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
FR2683915A1 (en) * 1991-11-18 1993-05-21 Philips Electronique Lab APPARATUS FOR EXAMINING MEDIA BY ULTRASONIC ECHOGRAPHY.
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (en) * 1992-07-11 1994-01-13 Asta Medica Ag New phospholipid derivatives
DE4233044A1 (en) 1992-10-01 1994-04-07 Asta Medica Ag Phospholipid derivatives that contain higher elements of the 5th main group
US5958906A (en) 1992-10-01 1999-09-28 Asta-Medica Aktiengesellschaft Phospholipid derivatives containing higher elements of the fifth main group
DE19650778C2 (en) 1996-12-06 2001-01-04 Asta Medica Ag Use of dopamine receptor antagonists in palliative tumor therapy
JP3367892B2 (en) * 1997-05-22 2003-01-20 株式会社ヨシツカ精機 Multi-stage powder molding press
DE19835611A1 (en) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Novel phospholipids with synthetic, unsaturated alkyl and acyl chains
PT1135193E (en) * 1998-12-04 2003-01-31 Max Delbrueck Centrum AGENTS FOR THE TREATMENT OF TUMORS BASED ON LIPOSOMES AND COMPREHENDING TAMOXYPHEN
US6521879B1 (en) 2001-04-20 2003-02-18 Rockwell Collins, Inc. Method and system for controlling an LED backlight in flat panel displays wherein illumination monitoring is done outside the viewing area
DE10148067A1 (en) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Heat sterilizable alkyl phosphocholine liposomes
JP2005515224A (en) * 2002-01-14 2005-05-26 ダウ グローバル テクノロジーズ インコーポレイティド Drug nanoparticles from template emulsion
DE10203195A1 (en) * 2002-01-25 2003-08-07 Zentaris Ag Use of alkylphosphocholines in the preventive treatment of protozoal diseases
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
CN1646138B (en) * 2002-03-25 2010-05-26 碧欧塞根公司 Novel therapeutical use of agonist ligands specific to G2A receptor
WO2004012744A1 (en) * 2002-07-30 2004-02-12 Zentaris Gmbh Use of alkyl phosphocholines in combination with antitumor medicaments
BR0315840A (en) * 2002-10-30 2005-09-27 Makscientific Corp Anti-protozoan substituted ring phospholipids
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2006122716A1 (en) * 2005-05-18 2006-11-23 Heidelberg Pharma Gmbh Use of ether-linked lysophosphatidylcholines and alkylphosphocholines for the treatment of papilloma virus induced warts and sarcoids

Also Published As

Publication number Publication date
AU2006328479B2 (en) 2012-03-08
NO20082862L (en) 2008-08-27
EP1962862B1 (en) 2013-09-04
IL191695A0 (en) 2009-02-11
AU2006328479A1 (en) 2007-06-28
JP2009519999A (en) 2009-05-21
PL1962862T3 (en) 2014-01-31
RU2469727C2 (en) 2012-12-20
EP1962862A2 (en) 2008-09-03
IL191695A (en) 2013-12-31
JP5232009B2 (en) 2013-07-10
KR101378005B1 (en) 2014-03-27
WO2007071658A3 (en) 2007-10-04
CA2632449A1 (en) 2007-06-28
HK1124775A1 (en) 2009-07-24
KR20080081326A (en) 2008-09-09
AR058397A1 (en) 2008-01-30
WO2007071658A2 (en) 2007-06-28
RU2008129597A (en) 2010-01-27

Similar Documents

Publication Publication Date Title
UY30042A1 (en) NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.
UA99434C2 (en) Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
CO2018003168A2 (en) Kras expression modulators
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
ECSP20046463A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING TISSUES WITH ACIDIC OR HYPOXIC DISEASES
UY31673A1 (en) "UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211"
PE20151023A1 (en) TRIAZOLOPYRAZINES
CO6602146A2 (en) Combined use of cryda and cry1fa proteins for the management of insect resistance
CL2011000301A1 (en) Compounds derived from purine with immunomodulatory activity; pharmaceutical composition comprising them; and use of them in the treatment of allergic diseases, allergic rhinitis, asthma, infectious diseases and cancer.
BR112015010059A2 (en) adjuvant therapy with the tec family kinase inhibitor
CO2018008846A2 (en) Carboxamide derivatives useful as rsk inhibitors
CR11031A (en) STABLE DIGESTIVE ENZYME COMPOSITIONS
CO6640285A2 (en) 5-alkynyl pyrimidines
CL2011002548A1 (en) Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.
GT200900146A (en) AKT ACTIVITY INHIBITORS
ECSP12011830A (en) NEW COMPOUNDS.
UY34701A (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFIT
CR10310A (en) NEW COMPOUNDS
ECSP11010798A (en) 1,2,5-OXADIAZOLS AS INDOLAMINE INHIBITORS 2,3-DIOXYGENASE
NI201000044A (en) BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
UY30846A1 (en) OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
CO6331434A2 (en) NEW COMPOUNDS
BR112014008616A2 (en) antiviral compounds
UY29417A1 (en) ENDOPARASITICID AGENTS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160927